search
Back to results

Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland (ROBOPHYSE)

Primary Purpose

Pituitary Neoplasms

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
da Vinci® Si™
Sponsored by
Fondation Ophtalmologique Adolphe de Rothschild
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pituitary Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pituitary adenoma with a surgical indication : visual compression and chiasmal syndrome, intracranial hypertension , hormonal syndrome (hypopituitarism and hypersecretion ) , failure of medicamentous treatments for prolactinoma
  • No pituitary apoplexy (requiring emergency surgery)
  • Spontaneous oral opening greater than 35 mm

Exclusion Criteria:

  • Insufficient buccal opening
  • Intercurrent pathology of oropharyngeal and nasopharyngeal
  • Complicated forms of adenoma pituitary adenoma (invasive adenoma)
  • Hemostasis disorder
  • Phlebitis or active pulmonary embolism

Sites / Locations

  • Fondation Ophtalmologique Adolphe de Rothschild

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Transoral surgery

Arm Description

Outcomes

Primary Outcome Measures

Number of Patients Operated Via da Vinci Robot
Number of patients in which the entire sella turcica (including its anterior face) is seen during surgery and reached by the robotic arms

Secondary Outcome Measures

Duration of Surgery
Total duration of surgery: installation, mucosal time, sphenoidal time, resection and closure
Number of Severe Adverse Events
An adverse event occurring after the procedure is serious if it causes death, endangers the life of the person who is suitable for research, requires or prolongs hospitalization, causes a significant handicap, results in a congenital malformation, or is considered medically significant.
Duration of Hospitalization
Duration of hospitalization after surgery

Full Information

First Posted
April 4, 2016
Last Updated
March 3, 2021
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
search

1. Study Identification

Unique Protocol Identification Number
NCT02743442
Brief Title
Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland
Acronym
ROBOPHYSE
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Terminated
Study Start Date
March 2016 (Actual)
Primary Completion Date
March 2018 (Actual)
Study Completion Date
September 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Ophtalmologique Adolphe de Rothschild

4. Oversight

5. Study Description

Brief Summary
Over the past 30 years, endoscopic transnasal techniques have gained a major interest, and anatomic limits have been widened in order to extend neurosurgical applications. For many years, robotic-assisted surgery using the da Vinci system (Intuitive Surgical Inc, Sunnyvale, California, USA) has been greatly developed, especially in urology and gynecology. Robotic-assisted surgery has been performed for pharyngeal and laryngeal cancers in a minimally invasive perspective. A robot-assisted preliminary series demonstrated the ability to approach the sella via oral approach without traumatic injury of nasal or oral cavity. Transoral approach avoids the complications of the endonasal resection: synechia, rhinitis sicca anterior, primary and secondary atrophican rhinitis, and empty nose syndrome. The investigators recently published a cadaveric study of transoral robotic-assisted skull base surgery to approach the sella turcica (Neurosurgical Rev. 2014; 37:609-17). In this study, the investigators will propose a new minimally invasive technique of pituitary surgery by transoral approach assisted by the da Vinci robot in patients with pituitary adenoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pituitary Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Transoral surgery
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
da Vinci® Si™
Primary Outcome Measure Information:
Title
Number of Patients Operated Via da Vinci Robot
Description
Number of patients in which the entire sella turcica (including its anterior face) is seen during surgery and reached by the robotic arms
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Duration of Surgery
Description
Total duration of surgery: installation, mucosal time, sphenoidal time, resection and closure
Time Frame
3 hours
Title
Number of Severe Adverse Events
Description
An adverse event occurring after the procedure is serious if it causes death, endangers the life of the person who is suitable for research, requires or prolongs hospitalization, causes a significant handicap, results in a congenital malformation, or is considered medically significant.
Time Frame
6 months
Title
Duration of Hospitalization
Description
Duration of hospitalization after surgery
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pituitary adenoma with a surgical indication : visual compression and chiasmal syndrome, intracranial hypertension , hormonal syndrome (hypopituitarism and hypersecretion ) , failure of medicamentous treatments for prolactinoma No pituitary apoplexy (requiring emergency surgery) Spontaneous oral opening greater than 35 mm Exclusion Criteria: Insufficient buccal opening Intercurrent pathology of oropharyngeal and nasopharyngeal Complicated forms of adenoma pituitary adenoma (invasive adenoma) Hemostasis disorder Phlebitis or active pulmonary embolism
Facility Information:
Facility Name
Fondation Ophtalmologique Adolphe de Rothschild
City
Paris
ZIP/Postal Code
75019
Country
France

12. IPD Sharing Statement

Learn more about this trial

Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland

We'll reach out to this number within 24 hrs